The 2021 revised WHO guidelines reconstructed glioblastoma classification based on comprehensive molecular and genetic testing, in particular categorizing high-grade gliomas as IDH-mutant and IDH-wild-type based on isocitrate dehydrogenase gene mutation [30]. The gene discussed is IDH3A; the disease is central nervous system cancer.